How long does Wegovy weight loss actually take?

You've just started, and the scale hasn't moved yet

It's week three. The pen arrived in plain DPD packaging, you've put it in the fridge, you've done your first couple of injections, and the number on the scale is stubbornly similar to where it started. That's normal, and it's worth understanding why.

Semaglutide works as a GLP-1 receptor agonist, it mimics a gut hormone that signals fullness and slows digestion. But the starting dose of 0.25mg, which patients take for the first four weeks, is a tolerability dose. Its job is to let your body adjust without a wall of nausea hitting you. The appetite-suppressing effect at this dose is mild by design. Some people notice their hunger shifting in the first fortnight; others don't feel much at all until the dose increases.

By weeks five to eight, on the 0.5mg dose, most people report a clearer change in appetite and some measurable weight movement, and if you want to know how long it takes to lose weight on Wegovy, that timeline is a useful place to start building realistic expectations. This is roughly when our prescribers start hearing the phrase "I just forgot to finish my plate." For a closer look at what those early weeks typically involve, our page on how long Wegovy takes to work covers the mechanistic picture in more detail.

The practical point: give it at least six to eight weeks before judging whether the medicine is doing anything. Early slow progress is part of the expected process, not a sign it isn't working.

Months two to six: where most of the loss happens

The steepest rate of weight loss in the STEP 1 trial happened between roughly weeks eight and thirty-six, as participants moved through the titration steps toward the 2.4mg maintenance dose. Each dose increase (from 0.5mg to 1.0mg, then 1.7mg, then 2.4mg) typically landed another reduction in appetite and an acceleration in the rate of loss. The titration schedule is prescribed and monitored; a clinician decides the timing, not the patient.

In practical terms, many people lose one to two percent of their body weight per month during this middle phase, though the range is wide. Someone starting at 100kg might lose around twelve to fifteen kilograms across those first six months. Someone with a higher starting weight often sees a larger absolute loss for the same percentage. The NHS medicines page for semaglutide explains what to expect at each stage in plain language.

This phase is also where side effects tend to be most noticeable. Nausea, loose stools and fatigue are most common after a dose increase and usually settle within a week or two. Protein intake, hydration and pacing meals through the day all help. These are things to discuss with your prescriber rather than manage alone, a clinician-led service means you have someone to contact when you're not sure whether what you're feeling is expected.

If you're weighing up how Wegovy's timeline compares with the tirzepatide schedule, the weight-loss treatment overview gives a fair side-by-side picture.

Month six onwards: the plateau and what it actually means

Somewhere between six and twelve months, most people on Wegovy hit a plateau. The scale stops moving for weeks at a time. This is one of the most common reasons people contact us thinking something has gone wrong. In most cases, nothing has.

Weight loss slows as the body adapts to a lower energy state and as the gap between intake and expenditure narrows. The medicine is still suppressing appetite; the body has simply recalibrated. Some people see a second, smaller wave of loss after several months at a plateau; others maintain rather than continue to lose. Both outcomes are clinically meaningful. Maintaining a 10 to 15% loss long-term has real health benefits, even when the scale no longer shifts.

The STEP 1 trial ran 68 weeks specifically because researchers understood this shape: the curve flattens, but the medicine's role shifts from weight-loss driver to weight-loss defender. Stopping treatment before a stable maintenance phase is established tends to result in weight returning over months. That's not a reason to stay on it indefinitely without clinical review, it's a reason to treat the duration question as a conversation with your prescriber rather than a guess.

Our page on how long you take Wegovy goes into the duration evidence in detail, including what NICE guidance says about treatment length. If you're curious about how the timeline compares across different semaglutide forms, the semaglutide weight-loss timeline page covers that ground too.

What affects your timeline?

Two people on identical doses of Wegovy, eating similar amounts and doing similar levels of activity, can have meaningfully different timelines. Several factors shift the picture.

Starting weight matters. A higher starting BMI typically produces a larger absolute loss for the same percentage response. Metabolic rate, age, sex, how much muscle mass you carry and how consistently you take the injection all play a role. People who combine the medicine with dietary changes and increased physical activity consistently lose more than those relying on the injection alone, the clinical trials included lifestyle support for a reason.

Genetics also influence response. A meaningful minority of people lose substantially more than the trial average; a smaller proportion lose less. The 15% average hides a wide range, from around 5% to over 20%. A prescriber review at six months helps identify whether the response has been sufficient to justify continuing, NICE's appraisal of semaglutide (TA875) recommends stopping if weight loss is below 5% at that point on the maintenance dose.

If you're thinking about getting started and want to understand the access process, the page on how long it takes to receive Wegovy explains the steps from consultation to delivery. And if cost is part of your thinking, the Wegovy price comparison page sets out what honest private pricing looks like. Start with eligibility, though, a free consultation with our prescribers is the right first step before anything else.